Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Genmab A/S (GNMSF)

Genmab A/S (GNMSF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 17,925,762
  • Shares Outstanding, K 65,370
  • Annual Sales, $ 2,392 M
  • Annual Income, $ 631,910 K
  • 60-Month Beta 1.01
  • Price/Sales 7.49
  • Price/Cash Flow 21.52
  • Price/Book 4.27
Trade GNMSF with:
  • Price/Earnings ttm 22.96
  • Earnings Per Share ttm 11.85
  • Most Recent Earnings $3.63 on 02/14/24
  • Latest Earnings Date 05/08/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
265.3000 +2.83%
on 04/25/24
306.5500 -11.01%
on 04/04/24
-22.9100 (-7.75%)
since 04/01/24
3-Month
262.0000 +4.13%
on 02/13/24
323.0180 -15.54%
on 03/13/24
-7.9900 (-2.85%)
since 02/01/24
52-Week
262.0000 +4.13%
on 02/13/24
426.5000 -36.04%
on 05/11/23
-135.8899 (-33.25%)
since 05/01/23

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Genmab A/S is a biotechnology company. It specializes in development of antibody therapeutics for the treatment of cancer. The company's product pipeline includes DARZALEX(R), Arzerra(R), tisotumab vedotin, enapotamab vedotin, HexaBody-DR5/DR5(R) and DuoBody-CD3xCD20 (R),which are in clinical stage....

See More

Key Turning Points

3rd Resistance Point 291.5700
2nd Resistance Point 288.1000
1st Resistance Point 281.1600
Last Price 272.8100
1st Support Level 270.7500
2nd Support Level 267.2800
3rd Support Level 260.3400

See More

52-Week High 426.5000
Fibonacci 61.8% 363.6610
Fibonacci 50% 344.2500
Fibonacci 38.2% 324.8390
Last Price 272.8100
52-Week Low 262.0000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar